Last updated on April 17, 2014 at 11:13 EDT

Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader

April 22, 2013

JERUSALEM, April 22, 2013 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer
of oral delivery systems, announced today that the Company’s CEO Nadav Kidron has been
invited to be a panelist for a breakouts session at the BIO International Convention
[http://convention.bio.org ] in Chicago, Illinois, USA. The breakout session, titled “Can
Israel Become the Next Biotech Start-Up Nation?” will take place on Tuesday, April 23rd,
from 9:00-9:45am during the International Market Briefings Track
[http://mybio.zerista.com/event?event_order=start&event_page=1&owner=other&owner_id=395485&track_id=1792 ]

Panel Description:

In the last 20 years, Israel has become a model for high tech entrepreneurship. A
country of 8 million people, Israel is home to a vibrant academic biomedical research
sector, a global pharmaceutical company and several public biotech companies. Yet, the
success of Israel’s biotech sector pales in comparison to its high-tech industry. What can
be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it
be applied to biotech? What can Israel learn from other success models in biotechnology
such as Massachusetts or California? Which regional partnerships can best leverage
Israel’s potential? What is the optimal positioning for Israeli Biotech to encourage
biopharma companies and investors to step up their involvement?

For more information on the panel please visit:


The BIO International Convention is hosted by the Biological Industry Organization
(BIO) and is one of the largest and most widely attended annual conferences in the
biotechnology sphere. For more information on BIO Chicago please visit:


About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 30 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company’s
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com.

The company’s fact sheet, the content of which is not part of this press release, can
be viewed here
[http://oramed.com/ufiles/Oramed%20%20fact%20sheet%20April14,2013%20-%20v2-website.pdf ].

Forward-looking statements: This press release contains forward-looking statements.
For example, we are using forward-looking statements when we discuss our oral insulin and
oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a
clinical trials, respectively. These forward-looking statements are based on the current
expectations of the management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection for our
product candidates; competition from other pharmaceutical or biotechnology companies; and
our ability to obtain additional funding required to conduct our research, development and
commercialization activities. In addition, the following factors, among others, could
cause actual results to differ materially from those described in the forward-looking
statements: changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of validation of our
technology as we progress further and lack of acceptance of our methods by the scientific
community; inability to retain or attract key employees whose knowledge is essential to
the development of our products; unforeseen scientific difficulties that may develop with
our process; greater cost of final product than anticipated; loss of market share and
pressure on pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient; and final
that products may harm recipients, all of which could cause the actual results or
performance of Oramed to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes no obligation to
publicly release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Oramed, reference
is made to Oramed’s reports filed from time to time with the Securities and Exchange

        Company Contact:
        Oramed Pharmaceuticals
        Aviva Sherman
        Cell: +972-54-792-4438
        Office: +972-2-566-0001
        Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: PR Newswire